Accelerated Approval Conversion Could Mean ‘Breakthrough’ Loss

Sponsors of ‘breakthrough therapy’-designated investigational oncology products may need to identify a niche subpopulation that remains underserved when a competing product with accelerated approval in the same indication completes confirmatory trials.